Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab in Underrepresented Patients With Diabetic Macular Edema
NCT05224102Phase 4Active, not recruiting
- Sponsor
- Genentech
- Start
- Feb 2022
- Primary completion
- Jan 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 4 trial of faricimab in diabetic macular edema (DME), sponsored by Genentech. Started Feb 2022; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05224102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05224102.